CN115025230A - 一种乳化剂组合物及其在乳液中的应用 - Google Patents
一种乳化剂组合物及其在乳液中的应用 Download PDFInfo
- Publication number
- CN115025230A CN115025230A CN202210502659.1A CN202210502659A CN115025230A CN 115025230 A CN115025230 A CN 115025230A CN 202210502659 A CN202210502659 A CN 202210502659A CN 115025230 A CN115025230 A CN 115025230A
- Authority
- CN
- China
- Prior art keywords
- oil
- emulsion
- protein
- emulsifier
- emulsifier composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 105
- 239000003995 emulsifying agent Substances 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 25
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 14
- 244000068988 Glycine max Species 0.000 claims abstract description 14
- 150000004676 glycans Chemical class 0.000 claims abstract description 13
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 13
- 239000005017 polysaccharide Substances 0.000 claims abstract description 13
- 239000007908 nanoemulsion Substances 0.000 claims abstract description 10
- 235000019202 steviosides Nutrition 0.000 claims abstract description 10
- 229940013618 stevioside Drugs 0.000 claims abstract description 9
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 9
- -1 glucosyl stevioside Chemical compound 0.000 claims abstract description 6
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 5
- 241000219287 Saponaria Species 0.000 claims abstract description 3
- 239000003921 oil Substances 0.000 claims description 60
- 235000019198 oils Nutrition 0.000 claims description 60
- 239000002245 particle Substances 0.000 claims description 22
- 235000018102 proteins Nutrition 0.000 claims description 22
- 241000195493 Cryptophyta Species 0.000 claims description 16
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 13
- 239000008158 vegetable oil Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 12
- 239000003549 soybean oil Substances 0.000 claims description 12
- 235000012424 soybean oil Nutrition 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 8
- 108010084695 Pea Proteins Proteins 0.000 claims description 5
- 235000019707 mung bean protein Nutrition 0.000 claims description 5
- 235000019702 pea protein Nutrition 0.000 claims description 5
- 235000019498 Walnut oil Nutrition 0.000 claims description 4
- 239000003240 coconut oil Substances 0.000 claims description 4
- 235000019864 coconut oil Nutrition 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 4
- 235000021323 fish oil Nutrition 0.000 claims description 4
- 239000008170 walnut oil Substances 0.000 claims description 4
- 108010073771 Soybean Proteins Proteins 0.000 claims description 3
- 102000007544 Whey Proteins Human genes 0.000 claims description 3
- 108010046377 Whey Proteins Proteins 0.000 claims description 3
- 239000003925 fat Substances 0.000 claims description 3
- 235000019197 fats Nutrition 0.000 claims description 3
- 229940001941 soy protein Drugs 0.000 claims description 3
- 235000021119 whey protein Nutrition 0.000 claims description 3
- 241001300674 Plukenetia volubilis Species 0.000 claims description 2
- 235000019705 chickpea protein Nutrition 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 229940106134 krill oil Drugs 0.000 claims description 2
- 239000000944 linseed oil Substances 0.000 claims description 2
- 235000021388 linseed oil Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims 2
- 235000019486 Sunflower oil Nutrition 0.000 claims 1
- 239000002600 sunflower oil Substances 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 abstract description 23
- 238000013329 compounding Methods 0.000 abstract description 12
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000003647 oxidation Effects 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 3
- 238000001556 precipitation Methods 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000008183 oral pharmaceutical preparation Substances 0.000 abstract description 2
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 description 17
- 238000004659 sterilization and disinfection Methods 0.000 description 15
- 238000005189 flocculation Methods 0.000 description 12
- 230000016615 flocculation Effects 0.000 description 12
- 230000007935 neutral effect Effects 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 208000022639 SchC6pf-Schulz-Passarge syndrome Diseases 0.000 description 8
- 208000001364 Schopf-Schulz-Passarge syndrome Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000032798 delamination Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000014593 oils and fats Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 235000020238 sunflower seed Nutrition 0.000 description 3
- 241001454523 Quillaja saponaria Species 0.000 description 2
- 235000009001 Quillaja saponaria Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000004383 Steviol glycoside Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000001553 co-assembly Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108010079923 lambda Spi-1 Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000005528 milk analysis Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229930182488 steviol glycoside Natural products 0.000 description 1
- 235000019411 steviol glycoside Nutrition 0.000 description 1
- 150000008144 steviol glycosides Chemical class 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种乳化剂组合物及其在乳液中的应用,所述乳化剂组合物包含质量比为0.2‑3:0.1‑3:0.1‑1的蛋白、可溶性大豆多糖与小分子乳化剂,所述小分子乳化剂选自甜菊糖苷、葡萄糖基甜菊糖苷、皂树皮提取物中的一种或多种。通过复配特定比例的蛋白、可溶性大豆多糖与小分子乳化剂得到乳化剂组合物,使蛋白在酸性条件下可稳定存在,不发生沉淀。将该乳化剂组合物用于制备酸性纳米乳液,可用作口服药物制剂,用于实现多种治疗效用,如调节血脂和/或清理血栓。另可解决富含ω‑3多不饱和脂肪酸油脂易氧化、乳液稳定性差等问题,有利于提高人体对ω‑3多不饱和脂肪酸的吸收。
Description
技术领域
本发明属于功能性组合物领域,尤其涉及一种乳化剂组合物及其在乳液中的应用,用作口服药物制剂时,以改善受试者的身体状态、预防或治疗相关的疾病或病症。
背景技术
ω-3多不饱和脂肪酸主要是α-亚麻酸(ALA)、二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)。ω-3多不饱和脂肪酸具有降血压和胆固醇、保护心血管、预防类风湿性关节炎、预防抑郁症、防止骨质疏松等功效。但ω-3多不饱和脂肪酸对氧气、光和热等较为敏感,稳定性较差,极易氧化变质;此外,ω-3多不饱和脂肪酸氧化产生的鱼腥味等不友好风味令消费者难以接受。
现有药品、食品中,常将富含ω-3多不饱和脂肪酸的藻油、鱼油等油脂制备成软胶囊剂型,该剂型虽有利于稳定油脂、对油脂进行保护,但对婴幼儿、老年人等吞咽困难人群存在食用不便的问题。因此,提高ω-3多不饱和脂肪酸的稳定性、改善食品食用不便等具有重量的意义。
为改善ω-3多不饱和脂肪酸的稳定性及服用或食用不便等问题,常将富含ω-3多不饱和脂肪酸的藻油、鱼油等油脂制备成纳米乳液等剂型。目前,用于制备纳米乳液的乳化剂主要分为两种,一是合成的小分子表面活性剂,如吐温类、司盘、琥珀酸单甘油酯、蔗糖脂肪酸酯等,但合成的小分子表面活性剂的用量较大,存在潜在的安全性,不符合现代食品工业的发展趋势;二是动物蛋白酶解后的多肽,但多肽的制备工艺繁琐,不适用于大规模的工业生产。因此,开发具有良好界面活性的天然乳化剂组合物,制备出具有高稳定性的纳米乳液,实现富含ω-3多不饱和脂肪酸油脂的乳液及产品的高效生产是亟待解决的问题。
蛋白不含胆固醇、饱和脂肪,可以提供肽、氨基酸等健康成分,具有降血脂、防癌和抗衰老等功效,是一种具有良好界面活性的天然乳化剂。口服液、乳液等剂型在中性条件下存在货架期短等问题,而将口服液、乳液等剂型制备成酸性产品能大大提高货架期,因此现有乳液产品等多为酸性。但蛋白质的等电点小于7,在酸性条件下,蛋白质溶解性下降,产生沉淀,乳化性能大大降低,难以实现有效乳化进而造成产品不稳定。因此,开发含蛋白的乳化剂组合物,用于制备酸性稳定的富含ω-3多不饱和脂肪酸的纳米乳液并应用于产品,可拓宽蛋白在乳液等药品、食品等领域中的应用范围,具有重大意义。
发明内容
针对上述现有技术中的不足,本发明的目的在于提供一种乳化剂组合物。通过复配特定比例的蛋白、可溶性大豆多糖与小分子乳化剂得到乳化剂组合物,使蛋白在酸性条件下可稳定存在,不发生沉淀。将该乳化剂组合物用于制备酸性纳米乳液,解决富含ω-3多不饱和脂肪酸油脂易氧化、乳液稳定性差等问题,有利于提高人体对ω-3多不饱和脂肪酸的吸收。
本发明的目的在于提供一种乳化剂组合物,所述乳化剂组合物包含质量比为0.2-3:0.1-3:0.1-1的蛋白、可溶性大豆多糖与小分子乳化剂,所述小分子乳化剂选自甜菊糖苷、葡萄糖基甜菊糖苷、皂树皮提取物中的一种或多种。
本方案采用蛋白、可溶性大豆多糖与小分子乳化剂作为复配乳化剂,以大分子蛋白乳化剂和可溶性大豆多糖为天然结构单元,利用天然小分子乳化剂(皂皮皂苷、甜菊糖苷等)镶嵌进大分子乳化剂(蛋白、可溶性大豆多糖)结构单元形成更稳定的乳化剂体系。此外,可溶性大豆多糖、甜菊糖苷、葡萄糖基甜菊糖苷、皂树皮提取物中含有羧基、羟基和羰基,与蛋白中的羧基、羟基和氨基等存在静电作用和氢键作用,形成共组装结构,从而使蛋白在酸性条件下稳定存在,进而形成稳定性的乳液。
优选地,所述蛋白选自大豆蛋白、绿豆蛋白、豌豆蛋白、鹰嘴豆蛋白、乳清蛋白中的一种或多种。
优选地,乳化剂组合物应用于口服液、乳液、果冻、油脂粉或滴剂等剂型产品中。
本方案所采用的乳化剂组合物制备的乳液可改善富含ω-3多不饱和脂肪酸油脂产品的服用、食用不便和吸收利用度低等问题。
本发明另一目的在于提供一种乳液,所述乳液包括质量含量为0.4%-7%的上述乳化剂组合物。
优选地,所述乳液还包括1%-30%的油相,油相包括20%-90%的富含ω-3多不饱和脂肪酸油脂,所述富含ω-3多不饱和脂肪酸油脂的ω-3多不饱和脂肪酸含量超过20%。
优选地,所述油脂选自藻油、鱼油、磷虾油、亚麻籽油、美藤果油中的一种或多种。
优选地,所述油相还包括10%-80%普通植物油,所述普通植物油中的ω-3多不饱和脂肪酸含量不超过20%。
本发明通过添加一定比例的普通植物油增加油相的黏度与密度,改善乳液液滴易聚集、乳析等问题,增强乳液热稳定性及储存稳定性。
优选地,所述普通植物油选自大豆油、葵花籽油、椰子油、玉米油、核桃油中的一种或多种。
优选地,所述乳液还包括63%-98.6%的水。
优选地,所述乳液为水包油型纳米乳液。
优选地,所述乳液的粒径为150-600nm,Zeta电位为±20mV至±50mV,pH为3.0-5.5。
本发明另一目的在于提供一种乳液的制备方法,包括如下步骤:
步骤S1.将乳化剂组合物与水按0.4-7:63-98.6质量比混合,所述乳化剂组合物中蛋白、可溶性大豆多糖与小分子乳化剂的质量比为0.2-3:0.1-3:0.1-1,搅拌溶解,调节pH至3.0-5.5;
步骤S2.将富含ω-3多不饱和脂肪酸油脂与普通植物油按2-9:1-8的质量比混合,室温搅拌均匀;
步骤S3.将步骤S1的混合物与步骤S2的混合物按70-99:1-30的质量比混合,剪切,得粗乳液;
步骤S4.将上述粗乳液均质、灭菌处理,灭菌温度为80-121℃,灭菌时间15-30min。
本发明另一目的在于提供上述的乳化剂组合物在药品、食品、保健品或化妆品中的应用。
本发明另一目的在于提供上述的乳液在药品、食品、保健品或化妆品中的应用。
相比于现有技术,本发明具有如下有益效果:
(1)通过复配特定比例的蛋白、可溶性大豆多糖与小分子乳化剂得到乳化剂组合物,使蛋白在酸性条件下可稳定存在,不发生沉淀。将该乳化剂组合物用于制备酸性纳米乳液,解决富含ω-3多不饱和脂肪酸油脂易氧化、乳液稳定性差等问题,有利于提高人体对ω-3多不饱和脂肪酸的吸收。
(2)单独采用蛋白或可溶性大豆多糖苷等乳化剂制备得到的乳液大多应用于中性环境,而本发明制备得到的乳液适用于酸性体系,乳液粒径小、热稳定性佳,可耐受80-121℃高温杀菌,适用于工业生产。
(3)用于制备乳液的物料均为天然来源,来源广泛且可直接通过商业渠道购得,符合现代市场对天然、健康的追求,符合食品行业对“清洁标签”的发展趋势。
(4)本发明的乳液制备过程简便快捷,可一步实现乳液的制备,有利于产业化。
附图说明
图1为乳液121℃灭菌15min后评估液面的浮油情况。
图2为乳液121℃灭菌15min后评估液面分层严重程度。
图3为对比例15的乳液储存7天后外观。
图4为对比例11、对比例12和实施例3(顺序从左到右)在不同pH值下的乳液外观图。
图5.含豌豆蛋白和绿豆蛋白的乳液粒径分布图。
图6为不同质量比的藻油与大豆油复配制备的乳液经过121℃,15min灭菌后的外观图(藻油与大豆油的质量比分别为10:0、9:1、5:5和1:4)。
图7为不同种类植物油与藻油复配制备的乳液外观图。
具体实施方式
为了使本技术领域的人员更好地理解本发明中的技术方案,下面将结合本发明实施例对本发明的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都应当属于本发明保护的范围。
术语:
SPI:大豆蛋白。
MPI:绿豆蛋白。
PPI:豌豆蛋白。
WPI:乳清蛋白。
SSPS:可溶性大豆多糖。
STE:甜菊糖苷。
QS:皂树皮提取物。
/:代表乳化剂组合物中的组分添加量为0或乳液严重浮油、分层或絮凝,无法测定粒径和PDI的数据。
实施例1.乳液的制备方法。
步骤S1.将乳化剂组合物与水按0.4-7:63-98.6质量比混合,所述乳化剂组合物中蛋白、可溶性大豆多糖与小分子乳化剂的质量比为0.2-3:0.1-3:0.1-1,搅拌溶解,调节pH至3.0-5.5;
步骤S2.将富含ω-3多不饱和脂肪酸油脂与普通植物油按2-9:1-8的质量比混合,室温搅拌均匀;
步骤S3.将步骤S1的混合物与步骤S2的混合物按70-99:1-30的质量比混合,剪切,得粗乳液;
步骤S4.将上述粗乳液均质、灭菌处理,灭菌温度为80-121℃,灭菌时间15-30min。
乳液粒径的测试及外观评价:
(1)粒径测试:
灭菌后乳液的粒径可采用微米粒度仪(Malvern 3000)和纳米粒度及电位仪(Nano-ZS Zeta)进行测定。测定物质为藻油,折射率设定为1.52,吸收率为0.001;分散相为水,折射率设定为1.33。若采用纳米粒度仪(Nano-ZS Zeta)测定,需要提前用pH为7.0的纯水将乳液稀释500-1000倍防止多重散射。
评价标准:粒度分布曲线峰越少、缝宽越窄,表明乳液液滴更均匀。
(2)外观评价:乳液121℃灭菌15min后评估液面的浮油及分层严重程度。灭菌后外观的不良可能是出现浮油(见说明书附图1)或者乳析分层(见说明书附图2);
评价指标如下:
++++:灭菌后严重浮油、分层或絮凝;
+++:灭菌后液面有明显浮油、分层或絮凝;
++:灭菌后液面有较明显的、不连续的浮油或絮凝;
+:灭菌后液面有少量浮油或絮凝;
-:灭菌后液面无浮油、无分层、无絮凝。
不同质量比原料组成的乳化剂组合物对乳液的影响:
表1.不同质量比原料组成的乳化剂组合物制备的乳液的性能测试结果。
由表1可知,SPI添加量为0.2%-3%、SSPS添加量为0.1%-3%、QS添加量为0.1%-1%可制备稳定酸性乳液。由实施例1-6可知,当SPI的添加量为0.2%-3%时,制备的中性和酸性乳液质量均良好,粒径较小;当SPI的添加量小于0.2%,制备的中性和酸性乳液粒径较大,灭菌后中性乳液有少量浮油,而酸性乳液则出现分层;当SPI的添加量大于3%时,制备的中性和酸性乳液均出现严重的絮凝或分层。由实施例7-12可知,当SSPS的添加量为0.1%-3%时,制备的中性和酸性乳液质量均良好,粒径较小;当SSPS的添加量小于0.1%,可制备出稳定的中性乳液,但酸性乳液出现严重的絮凝;当SSPS的添加量大于3%时,制备的中性和酸性乳液均出现絮凝。由实施例13-17可知,当QS的添加量为0.1%-1%时,制备的中性和酸性乳液质量均良好,粒径较小;当QS的添加量小于0.1%时,制备的中性和酸性乳液均出现絮凝;当QS的添加量大于1%时,制备的中性乳液粒较小,但酸性乳液粒径较大,灭菌后会出现明显的分层。
不同原料组成的乳化剂组合物对乳液的影响:
表2.不同原料组成的乳化剂组合物制备的乳液的性能测试结果。
由表2可知,单独采用SPI、SSPS或小分子乳化剂制备得到的对比例1-4的乳液,灭菌后乳液分别出现絮凝、粒径大、油水分层、乳析絮凝等现象;采用SPI复配小分子乳化剂制备得到的对比例5-11的乳液,灭菌后乳液出现严重浮油、分层或絮凝;采用SSPS复配小分子乳化剂制备得到的对比例12-14的乳液,灭菌后乳液粒径较大,久置之后容易产生上浮,不能形成稳定的乳液;采用小分子乳化剂复配制备得到的对比例15的乳液,灭菌后乳液出现严重浮油、分层或絮凝。对比例15的乳液储存7天后外观如图3所示,对比例11、对比例12和实施例3在不同pH值下的乳液外观图如图4所示。
不同蛋白、不同乳化剂小分子、不同ω-3多不饱和脂肪酸含量的油脂在不同的pH值下对乳液的影响:
表3.不同原料组成的乳化剂组合物制备的乳液的性能测试结果。
由表3可知,分别采用PPI、MPI、WPI与小分子乳化剂QS、STE、QS和STE、油相(藻油:大豆油)含量为10%、20%、30%进行复配在pH3、pH4、pH5.5下均能制备出粒径较小,稳定性良好的酸性乳液。从图5中可以看出,在表3的乳化剂配方中,豌豆蛋白和绿豆蛋白都能制备出粒径较小(<600nm)且分散均匀的藻油乳液。
不同质量比的藻油与大豆油复配对乳液的影响:
表4.不同质量比的藻油与大豆油复配制备的乳液的性能测试结果。
由表4和图6可知,只含有藻油的乳液在加热后出现明显的油析现象,表明乳液热稳定性较差。含有大豆油的乳液在加热后均没有出现明显的乳析、油析等现象,表明大豆油的加入能显著改善乳液的热稳定性。实验结果:
(1)采用纯藻油制备酸性乳液热灭菌后出现油析,乳液不稳定;
(2)油相藻油复配大豆油的乳液在加热后均没有出现明显的乳析、油析等现象,表明大豆油的加入能显著改善乳液的热稳定性。
图6为不同质量比的藻油与大豆油复配制备的乳液经过121℃,15min加热后的外观图。
分别采用葵花籽油、椰子油、核桃油与藻油复配对乳液的影响。
表5.不同种类植物油与藻油复配制备的乳液的性能测试结果。
样品 | 实施例28 | 实施例29 | 实施例30 |
植物油 | 葵花籽油 | 椰子油 | 核桃油 |
油相(藻油:植物油=9:1) | 10 | 10 | 10 |
水 | 87.6 | 87.6 | 87.6 |
SPI | 1 | 1 | 1 |
SSPS | 0.5 | 0.5 | 0.5 |
STE | 0.5 | 0.5 | 0.5 |
QS | 0.4 | 0.4 | 0.4 |
外观 | - | - | - |
粒径(nm) | 324.4 | 333.5 | 309.1 |
氧化诱导期/h | 1:58 | 2:06 | 1:18 |
由表5和图7可知,藻油与不同植物油复配制备的乳液经过121℃、15min的加热后,乳液的外观并没有出现明显变化,表明其他植物油的加入也能增强藻油乳液的热稳定性。其中,图7中,从左到右分别为实施例28、实施例29、实施例30制得的乳液。
最后应当说明的是,以上实施例仅用以说明本发明的技术方案而非对其限制,尽管对照上述实施例对本发明进行了详细的说明,所属领域的普通技术人员应当理解,技术人员阅读本申请说明书后依然可以对本发明的具体实施方式进行修改或者等同替换,但这些修改或变更均未脱离本发明申请待批权利要求保护范围之内。
Claims (12)
1.一种乳化剂组合物,其特征在于,所述乳化剂组合物包含质量比为0.2-3:0.1-3:0.1-1的蛋白、可溶性大豆多糖与小分子乳化剂,所述小分子乳化剂选自甜菊糖苷、葡萄糖基甜菊糖苷、皂树皮提取物中的一种或多种。
2.如权利要求1所述的乳化剂组合物,其特征在于,所述蛋白选自大豆蛋白、绿豆蛋白、豌豆蛋白、鹰嘴豆蛋白、乳清蛋白中的一种或多种。
3.如权利要求1或2所述的乳化剂组合物,其特征在于,所述乳化剂组合物应用于口服液、乳液、果冻、油脂粉或滴剂等剂型产品中。
4.一种乳液,其特征在于,所述乳液包括质量含量为0.4%-7%的权利要求1或2所述的乳化剂组合物。
5.如权利要求4所述的乳液,其特征在于,所述乳液还包括1%-30%的油相,所述油相包括20%-90%的富含ω-3多不饱和脂肪酸油脂,所述富含ω-3多不饱和脂肪酸油脂的ω-3多不饱和脂肪酸含量超过20%。
6.如权利要求5所述的乳液,其特征在于,所述油脂选自藻油、鱼油、磷虾油、亚麻籽油、美藤果油中的一种或多种。
7.如权利要求5所述的乳液,其特征在于,所述油相还包括10%-80%普通植物油,所述普通植物油中的ω-3多不饱和脂肪酸含量不超过20%。
8.如权利要求7所述的乳液,其特征在于,所述普通植物油选自大豆油、葵花籽油、椰子油、玉米油、核桃油中的一种或多种。
9.如权利要求4-8任一项所述的乳液,其特征在于,所述乳液为水包油型纳米乳液。
10.如权利要求4-8任一项所述的乳液,其特征在于,所述乳液的粒径为150-600nm,Zeta电位为±20mV至±50mV,pH值为3.0-5.5。
11.如权利要求1所述的乳化剂组合物在药品、食品、保健品或化妆品中的应用。
12.如权利要求4所述的乳液在药品、食品、保健品或化妆品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210502659.1A CN115025230A (zh) | 2022-05-10 | 2022-05-10 | 一种乳化剂组合物及其在乳液中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210502659.1A CN115025230A (zh) | 2022-05-10 | 2022-05-10 | 一种乳化剂组合物及其在乳液中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115025230A true CN115025230A (zh) | 2022-09-09 |
Family
ID=83120439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210502659.1A Pending CN115025230A (zh) | 2022-05-10 | 2022-05-10 | 一种乳化剂组合物及其在乳液中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115025230A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115644429A (zh) * | 2022-11-21 | 2023-01-31 | 华南理工大学 | 一种乳清蛋白-豆类蛋白共稳定的全营养特殊医学用途配方食品乳剂及其制备方法 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001046851A (ja) * | 1999-08-12 | 2001-02-20 | Fuji Oil Co Ltd | 乳化剤組成物及びこれを用いた酸性水中油型乳化物 |
CN102524637A (zh) * | 2010-12-23 | 2012-07-04 | 帝斯曼知识产权资产管理有限公司 | 包含植物蛋白-大豆多糖复合物的脂溶性活性成分的组合物 |
CN103269605A (zh) * | 2010-12-23 | 2013-08-28 | 帝斯曼知识产权资产管理有限公司 | 包含植物蛋白-大豆多糖复合物的脂溶性活性成分的组合物 |
CN104872498A (zh) * | 2015-05-15 | 2015-09-02 | 华南理工大学 | 一种植物蛋白/大豆多糖纳米乳液及其制备方法 |
CN105310066A (zh) * | 2015-11-09 | 2016-02-10 | 华南理工大学 | 一种包埋天然脂溶性色素的植物蛋白/大豆多糖纳米乳液及制法 |
CN105669825A (zh) * | 2016-02-18 | 2016-06-15 | 华南理工大学 | 一种基于可溶性大豆多糖的糖基化蛋白及其制备方法 |
CN112205475A (zh) * | 2019-07-10 | 2021-01-12 | 丰益(上海)生物技术研发中心有限公司 | 一种结构化乳液 |
CN113304697A (zh) * | 2021-04-12 | 2021-08-27 | 日照职业技术学院 | 一种南极磷虾油微粒及其制备方法 |
CN113876658A (zh) * | 2021-11-01 | 2022-01-04 | 仙乐健康科技股份有限公司 | 水包油型乳液组合物及其制备方法 |
CN114343190A (zh) * | 2021-12-10 | 2022-04-15 | 河南工业大学 | 一种利用皂树皮提取物提高植物蛋白乳化性能的方法 |
-
2022
- 2022-05-10 CN CN202210502659.1A patent/CN115025230A/zh active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001046851A (ja) * | 1999-08-12 | 2001-02-20 | Fuji Oil Co Ltd | 乳化剤組成物及びこれを用いた酸性水中油型乳化物 |
CN102524637A (zh) * | 2010-12-23 | 2012-07-04 | 帝斯曼知识产权资产管理有限公司 | 包含植物蛋白-大豆多糖复合物的脂溶性活性成分的组合物 |
CN103269605A (zh) * | 2010-12-23 | 2013-08-28 | 帝斯曼知识产权资产管理有限公司 | 包含植物蛋白-大豆多糖复合物的脂溶性活性成分的组合物 |
CN104872498A (zh) * | 2015-05-15 | 2015-09-02 | 华南理工大学 | 一种植物蛋白/大豆多糖纳米乳液及其制备方法 |
CN105310066A (zh) * | 2015-11-09 | 2016-02-10 | 华南理工大学 | 一种包埋天然脂溶性色素的植物蛋白/大豆多糖纳米乳液及制法 |
CN105669825A (zh) * | 2016-02-18 | 2016-06-15 | 华南理工大学 | 一种基于可溶性大豆多糖的糖基化蛋白及其制备方法 |
CN112205475A (zh) * | 2019-07-10 | 2021-01-12 | 丰益(上海)生物技术研发中心有限公司 | 一种结构化乳液 |
CN113304697A (zh) * | 2021-04-12 | 2021-08-27 | 日照职业技术学院 | 一种南极磷虾油微粒及其制备方法 |
CN113876658A (zh) * | 2021-11-01 | 2022-01-04 | 仙乐健康科技股份有限公司 | 水包油型乳液组合物及其制备方法 |
CN114343190A (zh) * | 2021-12-10 | 2022-04-15 | 河南工业大学 | 一种利用皂树皮提取物提高植物蛋白乳化性能的方法 |
Non-Patent Citations (1)
Title |
---|
邢琳琳: "大豆分离蛋白-多糖体系对甜菊糖苷苦味的抑制作用及其复合乳液稳定性研究", 《中国优秀硕士学位论文全文数据库工程科技I辑》, pages 024 - 284 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115644429A (zh) * | 2022-11-21 | 2023-01-31 | 华南理工大学 | 一种乳清蛋白-豆类蛋白共稳定的全营养特殊医学用途配方食品乳剂及其制备方法 |
CN115644429B (zh) * | 2022-11-21 | 2024-05-03 | 华南理工大学 | 一种乳清蛋白-豆类蛋白共稳定的全营养特殊医学用途配方食品乳剂 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Walker et al. | Development of food-grade nanoemulsions and emulsions for delivery of omega-3 fatty acids: Opportunities and obstacles in the food industry | |
Ivanov et al. | Flaxseed additive application in dairy products production | |
AU2002318135B2 (en) | Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes | |
KR101485874B1 (ko) | 혈중 지질 건강을 위한 식이 보충 조성물 | |
Julio et al. | Chia bilayer emulsions with modified sunflower lecithins and chitosan as delivery systems of omega-3 fatty acids | |
Genot et al. | Stabilization of omega-3 oils and enriched foods using emulsifiers | |
AU2006266755B2 (en) | Compositions ameliorating a reduced diurnal activity and/or depressive symptoms | |
EP1961312A2 (en) | Microbial oil mixture and uses thereof | |
Dong et al. | Oleogel-based Pickering emulsions stabilized by ovotransferrin–carboxymethyl chitosan nanoparticles for delivery of curcumin | |
Lane et al. | The development of vegetarian omega-3 oil in water nanoemulsions suitable for integration into functional food products | |
CN115025230A (zh) | 一种乳化剂组合物及其在乳液中的应用 | |
KR100951706B1 (ko) | 레스베라트롤을 함유하는 나노에멀젼, 나노입자 및 그제조방법 | |
Tiwari et al. | Toward the formulation of bio-cosmetic nanoemulsions: from plant-derived to microbial-derived ingredients | |
Ma et al. | Effects of lipid type and toxicological properties on the digestion of cellulose nanocrystals in simulated gastrointestinal tract | |
EP1679007B1 (en) | Oil-in-water type emulsion food | |
Yao et al. | Emulsifying properties of Chinese quince seed gum in oil-in-water emulsions | |
CN115644429B (zh) | 一种乳清蛋白-豆类蛋白共稳定的全营养特殊医学用途配方食品乳剂 | |
CN108531290A (zh) | 抑制鱼油中脂质氧化的方法 | |
CN111743996A (zh) | 一种具有增加记忆力改善老年痴呆口服乳剂及其制作方法 | |
CN108553419B (zh) | 一种α-亚麻酸乙酯微乳液及其制备方法 | |
CN107568731B (zh) | 一种辅酶q10鱼油纳米乳液及其制备方法与应用 | |
Tang et al. | Pseudosciaena crocea roe protein‐stabilized emulsions for oral delivery systems: In vitro digestion and in situ intestinal perfusion study | |
Diao et al. | The physicochemical properties, microstructure, and stability of diacylglycerol-loaded multilayer emulsion based on protein and polysaccharides | |
CN112574818A (zh) | 一种橄榄油Pickering乳液的制备方法 | |
Ma et al. | Constructing a Novel Oleogel Based on Decrystallization: Enhancing the Loading Efficiency and Bioaccessibility of Curcumin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |